Anzeige
Mehr »
Login
Sonntag, 13.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Antimon-Preise explodieren - Global Tactical sichert sich historische Green-Mine in Nevada!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
174 Leser
Artikel bewerten:
(1)

ArisGlobal: Global Pharma Organization Implements Advanced Signals as Part of LifeSphere Safety Platform

Finanznachrichten News

BOSTON, April 10, 2025 /PRNewswire/ -- ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, today announced that another top-tier pharmaceutical company has chosen LifeSphere Advanced Signals, a cutting-edge pharmacovigilance solution that leverages automation and AI-driven insights to streamline signal detection and management.

ArisGlobal Logo

This implementation marks a significant milestone -the customer represents ArisGlobal's largest and highest-volume deployment of LifeSphere Advanced Signals to date. The project underscores ArisGlobal's position as the partner of choice for safety modernization and highlights growing industry momentum toward intelligent signal automation and analytics.

LifeSphere Advanced Signals, powered by NavaX, delivers measurable impact, including:

  • 80% Faster Signal Assessment - Enable physicians to assess signals significantly faster compared to traditional manual methods.
  • 40-50% Reduced False Positives - Leverage fine-grain signal detection methods and advanced analytics to enhance accuracy and efficiency.
  • Ecosystem Harmonization - Reduce IT overhead and complexity with seamless integration with LifeSphere Safety and other third-party systems.
  • Enhanced Patient Safety - Drive better patient outcomes with accelerated access to insights that can help you proactively prevent potential risks before they arise.

By integrating LifeSphere Advanced Signals into their global safety ecosystem, this leading organization is better positioned to drive faster and more precise signaling, improve patient safety, and streamline pharmacovigilance workflows.

"We continue to see life sciences organizations prioritizing advanced signal detection as a critical component of their safety strategies," said Ann-Marie Orange, CIO and Global Head of R&D at ArisGlobal. "By integrating LifeSphere Advanced Signals, our customers are transforming pharmacovigilance by enabling earlier detection of safety issues, accelerating decision-making, and supporting more targeted risk management strategies. By leveraging intelligent automation and real-time data insights, we're not just improving regulatory compliance-we're proactively protecting patients and building greater trust in the safety of medicines worldwide."

ArisGlobal remains committed to advancing pharmacovigilance through AI-driven innovations, empowering organizations to navigate the complexities of modern drug safety management.

About ArisGlobal

ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming how today's most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn. www.arisglobal.com.

Logo - https://mma.prnewswire.com/media/1510670/ArisGlobal_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/global-pharma-organization-implements-advanced-signals-as-part-of-lifesphere-safety-platform-302425822.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.